DOCSLIB.ORG

The Pharmaceutical Industry in Germany

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Pharmaceutical Industry in Germany INDUSTRY OVERVIEW The Pharmaceutical Industry in Germany ISSUE 2017/2018 THE PHARMACEUTICAL INDUSTRY IN GERMANY An Ideal Location for Research, Production and Sales Germany offers the perfect location for the de- global growth markets, with the pharmaceutical velopment, production and sale of world-class industry in Germany already a significant global pharmaceuticals. The country benefits from industry player. Germany is home to Europe’s larg- cutting-edge research, a long production tradition est – and the world’s fourth largest – pharma- and immediate market access to pharmaceuticals. ceuticals market. A highly attractive R&D location, Global demand for pharmaceuticals is growing the country ranks first and second in clinical trial continuously as the result of a growing world terms in Europe and the world respectively. Hav- population and demographic change. Together ing established itself as the “world’s pharmacy” as with significant research advances, especially in part of a tradition of medical innovation, Germany the field of medical biotechnology, these develop- is also the world’s leading medical biopharmaceu- ments are providing a spur to the pharmaceutical ticals producer – second only to the USA. industry worldwide. The healthcare industry has evolved to become one of the most important Sweden Finland Russia Germany’s pharma- h by plane ceutical industry – Norway 3 at the market Estonia crossroads of Europe Latvia 1.5 h Lithuania Denmark RU Belarus Ireland UK Netherlands Poland 15 h 30 h by train Belgium GERMANY Ukraine Luxembourg Czechia Slovak Moldova Republic France Austria Hungary Romania Switzerland 12 h Slovenia Croatia Serbia Bosnia- Herzegovina Bulgaria Kosovo Montenegro h by truck Italy 24 Macedonia Portugal Albania Turkey Greece Spain Malta 2 Industry Overview 2017/18 | gtai.com The Industry in Numbers In 2014, healthcare spending in Germany totaled In Germany the generic volume share is much EUR 328 billion (more than four percent increase higher, having reached 77 percent in 2015 with a compared to 2013). This equates to 11.2 percent value of more than EUR 2 billion. Beyond conven- of German GDP (EUR 4,050 per capita). Of this tional medicines, natural medicines have gained a sum, 14 percent is spent on pharmaceutical significant share of the German pharmaceuticals products. Increased demand for medicines and market. Herbals and homeopathic medicines play the introduction of new drugs onto the market an increasingly significant role, particularly in the are the main drivers of spending growth accor- self-medication market. ding to the OECD. With its domestic pharmaceutical industry consisting of companies such as Bayer, BASF and Revenue and Growth in Germany’s Hoechst, Germany has a historical reputation as Pharmaceutical Industry the world’s pharmacy. The sector enjoys market stability. In 2014, the pharmaceutical industry Revenue in EUR billion consisted of more than 640 companies, employing Growth in percent 5.7 5.6 a workforce of 112,500. Pharmaceutical companies 5.4 can be found in all parts of Germany, with higher concentrations around the cities of Hamburg, Berlin, Cologne, Frankfurt, and Munich. With rev- enue of EUR 38 billion in 2015, Germany is the 2.0 1.6 world’s fourth-largest pharmaceuticals market. 380 Germany’s share of the global pharmaceutical 362 342 market remained at around 13.5 percent. The 326 319 pharmaceutical industry in Germany imported pharmaceuticals to the value of almost EUR 41 2011 2012 2013 2014 2015 billion in 2015 and recorded an export rate of nearly 66 percent in 2014. Source: Federal Statistical Office 2015 Pharmaceutical spending in the statutory health insurance sector reached a new high of EUR 37 billion in 2015, recording an annual spending increase of 4.3 percent or more than EUR 1.5 Employment in the Pharmaceutical Industry by billion. The number of packages sold in the Ger- Country 2015 man pharmacy market increased three percent from 1.43 billion in 2014 to 1.47 billion in 2015. Germn 112,475 The annual increase in the German pharmacy market – both in euro and unit transaction vol- umes – was largely achieved through prescription Frnce 92,650 drugs and pharmacy medicine. Generic medicines considerably contribute to European drug supply. Germany aims to balance between rewarding U 64,000 innovations through attractive pricing while, at the same time, fostering generics. In most European countries, the market share of generic Itl 63,000 medicines in volume terms exceeds 40 percent of generics-eligible segments. Source: EFPIA 2016 3 MARKET OPPORTUNITIES Largest Health Economy Growing Market Healthcare Expenditure in Germany Catering to the largest population in Europe (81 in EUR billion million), Germany’s healthcare sector is a highly attractive market with significant growth oppor- tunities. A steady increase in life expectancy levels has led to a rise of chronic and age-related illnesses. Improved health awareness has further increased consumer demand for medicinal prod- ucts and therapies. In 2014, healthcare spending 328 315 in Germany exceeded EUR 328 billion, not in- 303 296 cluding out-of-pocket expenditure for health- care (equivalent to 11.2 percent of GDP). Health Insurance Opportunities Germany provides ready access to a stable mar- 2011 2012 2013 2014 ket of healthcare consumers with a clear and Source: Federal Statistical Office 2015 adequately distributed expenditure system. The German healthcare system is funded by govern- ment and private contributions. The public system is largely financed by members’ contributions total healthcare expenses in 2015. Private health as payroll taxes by the employer and employed, insurance companies reimbursed an additional with the rest coming from government subsidies. EUR 23.2 billion of medical expenses. The remain- With around 88 percent of the German popula- ing amount is covered by government budgets, tion enrolled in a public health insurance plan, the state-mandated long-term care insurers, the social public health insurance system plays the major role pension fund, state-mandated accident insurance in the allocation of healthcare funds. An additional providers, employers, and private households. eleven percent of the population opts for private More than 20 percent of the publicly insured pop- health insurance. Germany’s 123 public health ulation has an additional private health insurance insurance providers covered EUR 213.7 billion of policy to complement their basic healthcare provi- sion. A recent development has been the trend amongst private individuals to spend more money on out-of-pocket medicine and therapy purchases. Pharmaceutical Market Share Differentiation Most out-of-pocket payments are made to pur- share of revenue chase over-the-counter (OTC) drugs and in the form of co-payments for prescribed drugs. Hospital Demographic Change market (13%) Longer life expectancy levels and declining fertil- Pharmacy Over-the-counter 12% Homeopathics 1% ity rates mean that older people account for a market (87%) Herbal medicines 2% larger proportion of the population in Germany. At least one quarter of the population will be over 65 Prescription only 75% Biotech 19% years of age in 2050. The proportion of the popu- lation aged over 80 is expected to almost triple between 2010 and 2050 (rising from 5 percent to Chemical products 65% 15 percent). Accelerating urbanization and more sedentary lifestyles lead to higher obesity rates and chronic diseases such as diabetes. According to the World Health Organization, worldwide chronic disease prevalence is expected to rise by 57 percent by the year 2020. Increased demand Prescription Product made on healthcare systems due to noncommuni- status type cable disease has become a major concern. Source: IMS Health Report 2016 4 Industry Overview 2017/18 | gtai.com Production Location High Production Standards Chemical Industry Strength Germany is an ideal production location for Pharmaceutical companies also benefit from research-intensive, high-grade products. It places the strong international position of the German a high value on technology; this stemming from chemical industry. As a location for the production the country’s long history of developing and man- of chemicals, Germany places first in Europe and ufacturing high-quality pharmaceutical products. third globally – accounting for a quarter of Euro- The country’s particular strength lies in producing pean chemical production in 2015. A number of complex products where containment and sterile outstanding chemical parks in Germany offer environments are critical. Hundreds of thousands specific infrastructural benefits to potential of highly skilled employees in medical-technical, pharmaceutical industry investors. pharmaceutical-technical and engineering back- grounds enable companies to utilize efficient and complex production processes. EU Pharmaceutical Industry Production 2014 Major Production Location in EUR billion Germany counts among the world’s top five phar- maceutical production locations, with a production volume of EUR 30.4 billion in 2014 (equivalent to an almost five percent increase over 2013). Within 304 290 the European Union, no other country produces more drugs than Germany. Internationally, Ger- many also has the largest fermentation capaci- 210 193193 ties – second only to the USA – and is home to 175 the very latest facilities for biomanufacturing. 175 139 Pharmaceutical companies in Germany also ben- efit from close proximity to leading machinery 139 and equipment manufacturers,
Load more

Recommended publications
  • The Innovation Paper
    CABC Policy Recommendations to Enhance Innovation in Canada cabc.co Summer 2016 Contents 03 Executive Summary 04 Introduction 06 Defining the Challenge 12 What Solutions Are Needed? 35 Conclusion – Solutions Are Within Reach 50 About CABC CABC Policy Recommendations to Enhance Innovation in Canada 2 Executive Summary The Canadian American Business Council is pleased to offer the following recommendations for consideration by the Government of Canada to advance its innovation agenda and help grow the economy of North America. The recommendations that follow are designed to be achievable and affordable within the next three to five years, without requiring additional public expenditures beyond what has been outlined in the federal budget. While the Canadian economy enjoys sound fundamentals and many advantages, Canada currently has a widely recognized “innovation problem” which the government and multiple stakeholders, including CABC, are committed to addressing. Canada has slipped in the World Economic Forum’s Global Competiveness Ranking, falling from 11th to 22nd place in one year. The Conference Board ranks Canada 13 out of 16 in innovation and investment in R&D compared to its peers. The good news is that the Government of Canada is committed to addressing innovation impediments, and CABC has specific actionable recommendations that could help substantially. This paper outlines in detail our policy suggestions which include: • Strengthening links between Canada’s science base and industry; • Reforming the legal framework for innovation including the patent system; and • Improving the access of innovative small and start-up firms to risk capital; and to make capital available for early stage commercialization of innovation.
    [Show full text]
  • Missions in a Changing World. the Bundeswehr and Its Operations
    SWP Research Paper Rainer L. Glatz, Wibke Hansen, Markus Kaim and Judith Vorrath Missions in a Changing World The Bundeswehr and Its Operations Abroad Stiftung Wissenschaft und Politik German Institute for International and Security Affairs SWP Research Paper 6 September 2018 Abstract Military operations abroad by the German Armed Forces are always a con- troversial instrument of German crisis management. Yet, such foreign deployments are likely to remain necessary for the foreseeable future while, at the same time, they are undergoing noticeable change. The conditions shaping this transformation can be captured in three dimensions of change: the change in war and violent conflict; the transformation of the inter- national political and legal context; and the shifting institutional frame- works for these operations. German policy-makers must address the related challenges – whether setting normative anchors and formats for operations, contributing to sta- bilisation in a context of continuing insecurity, building partners’ military capacities, dealing with transnational threats or using benchmarks for exiting. Yet, they only have limited influence over the described changes. Fundamentally, decisions about military operations abroad are taken within the triangle of pressing problems (crises and conflicts), responsibility (obli- gations under international law, alliances, political commitments), and the political situation and available capabilities in Germany itself. It is hard to predict the developments which will dictate the scope for action within this triangle. However, the worst possible approach would be to address the described challenges only from a short-term and ad-hoc perspective, especially since they do not exclusively concern operations abroad. In its 2017 Guidelines on crisis prevention and conflict resolution and 2016 White Paper, the German federal government outlined a frame- work for German engagement that it now has to fill.
    [Show full text]
  • Germany: Reluctant Land of Immigration
    G E R M A N I S S U E S GERMANY: RELUCTANT LAND OF IMMIGRATION PHILIP L. MARTIN GERMAN ISSUES 21 American Institute for Contemporary German Studies The Johns Hopkins University GERMANY: RELUCTANT LAND OF IMMIGRATION PHILIP L. MARTIN GERMAN ISSUES 21 The American Institute for Contemporary German Studies (AICGS) is a center for advanced research, study, and discussion on the politics, culture, and society of the Federal Republic of Germany. Established in 1983 and affiliated with The Johns Hopkins University but governed by its own Board of Trustees, AICGS is a privately incorporated institute dedicated to independent, critical, and comprehensive analysis and assessment of current German issues. Its goals are to help develop a new generation of American scholars with a thorough understanding of contemporary Germany, deepen American knowledge and understanding of current German developments, contribute to American policy analysis of problems relating to Germany, and promote interdisciplinary and comparative research on Germany. Executive Director: Jackson Janes Research Director: Carl Lankowski Board of Trustees, Cochair: Steven Muller Board of Trustees, Cochair: Harry J. Gray The views expressed in this publication are those of the author(s) alone. They do not necessarily reflect the views of the American Institute for Contemporary German Studies. ©1998 by the American Institute for Contemporary German Studies ISBN 0-941441-32-6 Additional copies of this AICGS German Issue are available from the American Institute for Contemporary German Studies, Suite 420, 1400 16th Street, N.W., Washington, D.C. 20036-2217. Telephone 202/332-9312, Fax 202/265-9531, E-mail: [email protected], Web: http://www.jhu.edu/~aicgsdoc/ C O N T E N T S Foreword ..............................................................................................
    [Show full text]
  • Still on the Way to Afghanistan? Germany and Its Forces in the Hindu Kush
    Still on the way to Afghanistan? Germany and its forces in the Hindu Kush A SIPRI Project Paper Sebastian Merz* November 2007 I. Introduction Deployment of military forces to foreign countries by the Federal Republic of Germany has become more common in recent years. The 2006 decision to provide troops for the UN mission in Lebanon was the most recent example (and the most unlikely precedent) of a German foreign and security policy that few would have predicted only a decade ago. While engagements in the Middle East and the Democratic Republic of the Congo have sometimes dominated political discourse, Germany’s largest mission is stationed in Afghanistan. Germany has been a major contributor to the North Atlantic Treaty Organization’s (NATO) International Security Assistance Force (ISAF), which was established in 2001 to provide and maintain security in support of the Afghan Govern- ment’s reconstruction efforts.1 Recently, German involvement in Afghanistan has been the focus of much public debate, mainly because of increased violence in the country and repeated NATO calls for German support for its counter-insurgency campaign. On 7 February 2007, the German Government decided to expand its military presence in Afghanistan at the specific request of NATO. Six Tornado aircraft were stationed in Mazar i Sharif to assist the alliance in surveillance operations, chiefly covering the troubled southern provinces.2 The decision came after a lengthy debate, which clearly exposed the growing discomfort of many Germans with their country’s military role in Afghanistan. Currently Germany has approximately 3000 military personnel in Afghanistan. These are divided between Kabul and the northern provinces, where there is a larger base in Mazar i Sharif as well as two provincial reconstruction teams (PRTs), in Kunduz and Feyzabad.
    [Show full text]
  • DOCUMENT RESUME ED 384 553 SO 024 877 AUTHOR Blankenship, Glen; Tinkler, D. William TITLE the Geography of Germany: Lessons
    DOCUMENT RESUME ED 384 553 SO 024 877 AUTHOR Blankenship, Glen; Tinkler, D. William TITLE The Geography of Germany: Lessons for Teaching the Five Themes of Geography. PUB DATE 93 NOTE 95p.; For related volume of social studies lessons, see SO 024 876. PUB TYPE Guides Classroom Use Teaching Guides (For Teacher) (052) EDRS PRICE MF01/PC04 Plus Postage. DESCRIPTORS Area Studies; Elementary Secondary Education; Foreign Countries; Fundamental Concepts; *Geographic Concepts; Geographic Location; *Geography; *Geography Instruction; History; Human Geography; Physical Geography; Social Studies; Teaching Guides; Teaching Methods; Western Civilization IDENTIFIERS *Germany ABSTRACT This activity guide contains five lessons. Lesson 1 deals with "Location of Germany on the Earth's Surface" with two activities:(1) "Germany's Location in the World"; and (2) "Germany's Location in Europe." Lesson 2 is on the "Physical and Human Characteristics of Germany" with four activities on:(1) "Physical Features of Germany";(2) "Germany's Population Pyramid"; (3) " Population Density in Germany"; and (4) "Population Distribution in Germany." Lesson 3 addresses "The Interaction of the German People and Their Environment" with four activities: (1) "Land Use in Germany";(2) "Industrial Areas in Germany"; (3) "Pollution in Germany"; and (4) "The Environment." Lessc- 4 highlights "Movement and Diversity in Germany" with two activities:(1) "Foreigners in Germany"; and (2) "Immigration to Germany." Lesson 5 develops the theme of "German Unification and Regional Changes" with aix activities: (1) "Regions in Germany";(2) "German Unification"; (3) "Opening the Berlin Wall";(4) "East German Perspectives on Unification, Part A";(5) "East German Perspectives on Unification, Part B"; and (6) "World Press Views on Unification." Complete handouts and instruc'tions accompany the lessons.
    [Show full text]
  • Biotechnology| Life Sciences in Munich/Germany
    Biotechnology | Life Sciences in Munich/Germany Final Report Gwarlann De Kerviler Maria Levis Kiyoshi Nakazawa Stephanie Sealy Lars Zimmermann Professor Michael Porter HBS 1260/PED 329 May 4, 2007 TABLE OF CONTENTS DISCLAIMER ..................................................................................................................................03 PREFACE...........................................................................................................................................03 I. Introduction: Germany at a Glance ....................................................................................05 I.1 Background..............................................................................................................................05 I.2 History ......................................................................................................................................08 I.3 Context......................................................................................................................................10 3.1 Macroeconomic Context ............................................................................................................10 3.2 Political Context ........................................................................................................................11 3.3 Legal Context .............................................................................................................................12 3.4 Socio-Cultural Context..............................................................................................................12
    [Show full text]
  • BOOKLET 4 Drugs and Associated Issues Among Young People and Older People PREFACE
    DRUGS AND AGE Drugs and associated issues among young people and older people ISBN 978-92-1-148304-8 WORLD DRUG 9 789211 483048 REPORT 2018 4 © United Nations, June 2018. All rights reserved worldwide. ISBN: 978-92-1-148304-8 eISBN: 978-92-1-045058-4 United Nations publication, Sales No. E.18.XI.9 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: https://www.unodc.org/wdr2018 PREFACE Both the range of drugs and drug markets are Drug treatment and health services continue to fall expanding and diversifying as never before.
    [Show full text]
  • Indian Investments in Germany Prospects for Shared Prosperity
    Indian Investments in Germany Prospects for Shared Prosperity Indian Investments in Germany Prospects for Shared Prosperity Bertelsmann Stiftung, Ernst & Young GmbH, Confederation of Indian Industry (CII) Table of Contents From the editors’ desk ................................................................................................ 5 Foreword ........................................................................................................................ 7 Executive summary ..................................................................................................... 8 Introduction and approach .................................................................................... 11 1 Indo-German business relations .................................................................................. 13 1.1 Germany and India in context ...................................................................... 13 Global focus: Multipolar world ............................................................... 13 Indo-German trade relations ................................................................... 15 1.2 Indian investment in Germany ..................................................................... 17 Indian FDI worldwide ................................................................................ 17 Hot topic | Brexit-related opportunities .............................................. 20 Indian M&A in Germany ........................................................................... 23 Hot topic | Opportunities
    [Show full text]
  • Germany - the Role of Competition Policy in Regulatory Reform 2003
    Germany - The Role of Competition Policy in Regulatory Reform 2003 The Review is one of a series of country reports carried out under the OECD’s Regulatory Reform Programme, in response to the 1997 mandate by OECD Ministers. This report on the role of competition policy in regulatory reform analyses the institutional set-up and use of policy instruments in Germany. This report was principally prepared by Mr. Michael Wise for the OECD. OECD REVIEWS OF REGULATORY REFORM REGULATORY REFORM IN GERMANY THE ROLE OF COMPETITION POLICY IN REGULATORY REFORM ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT © OECD (2004). All rights reserved. 1 ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT Pursuant to Article 1 of the Convention signed in Paris on 14th December 1960, and which came into force on 30th September 1961, the Organisation for Economic Co-operation and Development (OECD) shall promote policies designed: − to achieve the highest sustainable economic growth and employment and a rising standard of living in Member countries, while maintaining financial stability, and thus to contribute to the development of the world economy; − to contribute to sound economic expansion in Member as well as non-member countries in the process of economic development; and − to contribute to the expansion of world trade on a multilateral, non-discriminatory basis in accordance with international obligations. The original Member countries of the OECD are Austria, Belgium, Canada, Denmark, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The following countries became Members subsequently through accession at the dates indicated hereafter: Japan (28th April 1964), Finland (28th January 1969), Australia (7th June 1971), New Zealand (29th May 1973), Mexico (18th May 1994), the Czech Republic (21st December 1995), Hungary (7th May 1996), Poland (22nd November 1996), Korea (12th December 1996) and the Slovak Republic (14th December 2000).
    [Show full text]
  • Germany Country Drug Report 2017
    Germany Country Drug Report 2017 Contents: At a glance | National drug strategy and coordination (p. 2) | Public expenditure (p. 3) | Drug laws and drug law offences (p. 4) | Drug use (p. 5) | Drug harms (p. 8) | Prevention (p. 10) | Harm reduction (p. 11) | Treatment (p. 12) | Drug use and responses in prison (p. 14) | Quality assurance (p. 14) | Drug-related research (p. 15) | Drug markets (p. 16) | Key drug statistics for Germany (p. 18) | EU Dashboard (p. 20) THE DRUG PROBLEM IN GERMANY AT A GLANCE Drug use Treatment entrants Overdose deaths Drug law oences in young adults (18-34 years) by primary drug in the last year 1 600 292 227 Cannabis 1 400 1 226 1 200 1 000 13.3 % 800 Top 5 drugs seized 600 400 ranked according to quantities Cannabis, 39 % measured in kilograms Stimulants other 200 than cocaine, 17 % 0 1. Herbal cannabis 2011 2012 2013 2015 2014 Cocaine, 6 % 2010 2007 2008 2006 11 % 15.6 % 2009 Opioids, 33 % 2. Cocaine Other drugs Other, 5 % HIV diagnoses 3. Cannabis resin Amphetamines 1.9 % Opioid substitution attributed to injecting 4. Amphetamine MDMA 1.3 % treatment clients 160 5. Heroin Cocaine 1.2 % 140 134 120 Population 77 200 100 80 (15-64 years) 60 High-risk opioid users Syringes distributeddistributed 40 through specialised 20 53 422 103 programmes 160 322 0 2011 2012 2013 2015 2014 2010 2007 2008 No data 2006 2009 Source: EUROSTAT (146 580 - 174 064) Source: ECDC Extracted on: 26/03/2017 NB: Data presented here are either national estimates (prevalence of use, opioid drug users) or reported numbers through the EMCDDA indicators (treatment clients, syringes, deaths and HIV diagnosis, drug law offences and seizures).
    [Show full text]
  • Economic and Social Consequences of Drug Abuse and Illicit Trafficking Note
    Number 6 ECONOMIC AND SOCIAL CONSEQUENCES OF DRUG ABUSE AND ILLICIT TRAFFICKING NOTE References to dollars ($) are to United States dollars, unless otherwise stated. This publication has not been formally edited. Contents Introduction ............................................................ 1 I. Extent of the illicit drug problem ......................................... 3 A. Production ................................................... 4 B. Distribution and illicit trafficking ................................... 6 C. Consumption .................................................. 7 II. Economic consequences of drug abuse and trafficking ......................... 12 A. Apparent "benefits" and costs of drug abuse and trafficking .............. 12 1. “Benefits” ................................................ 12 2. Costs ................................................... 15 B. Work, employment and productivity ............................... 16 1. Influence of drugs on employment status and productivity ........... 16 2. Generation of employment ................................... 19 C. Prices and income ............................................. 20 1. Determinants ............................................. 20 2. Price elasticity ............................................ 23 3. Inflation ................................................. 25 4. Income distribution ......................................... 25 D. Trade and balance of payments ................................... 25 E. Finance and investment ........................................
    [Show full text]
  • The Pharmaceutical Sector
    HEALTH MADE IN GERMANY The Pharmaceutical Sector 1 The PharmaceuTical secTor Summary Germany is a major actor in the global healthcare sector and boasts a leading industry that devel- ops, produces and distributes high-quality phar- maceutical products serving markets worldwide. The pharmaceutical sector benefits from cutting- edge research facilities, a long tradition in manu- facturing and a highly diversified mix of large corporations as well as small and medium-sized enterprises (SMEs). Together, they form a strong base and provide the expertise necessary to meet the challenges of a changing global health market. This is best examplified by increasing pharmaceu- tical export volumes, especially in Asia and Latin America. Germany is also among the world’s top five pharmaceutical manufacturing services loca- tions. 13% of annual revenues are invested in Research and Development 660+ pharmaceutical companies are situated in Germany EUR 63.5 bn export sales generated by German pharmaceutical companies in 2016 594 clinical trials financed by pharmaceutical companies took place in Germany in 2016 2 The Pharmaceutical Sector | health-made-in-germany.com Market Data Global demand for high-quality drugs is con- Total Sales of German Pharmaceutical Products in Foreign Markets stantly rising due to a growing global population, in EUR billion improved healthcare standards and strengthened economies in non-industrialized countries. Accord- ing to IMS Health, global spending on medicine 62.5 63.5 will reach USD 1.5 trillion by 2021. The sector is 55.3 largely driven by innovation, a fact best demon- 52.5 50.1 strated by the high numbers of newly approved drugs in Europe.
    [Show full text]